{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T10:41:03Z","timestamp":1772707263384,"version":"3.50.1"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,3]]},"abstract":"<jats:sec>\n            <jats:title>Purpose of review<\/jats:title>\n            <jats:p>To discuss recent studies of lesinurad and arhalofenate.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Recent findings<\/jats:title>\n            <jats:p>Lesinurad acts by blocking urate reabsorption channels URAT-1 and OAT-4. It has urate-lowering effect when used alone and in combination with xanthine oxidase inhibitors (XOIs). Its uricosuric activity depends on glomerular filtration, and its\u2019 efficacy is impaired at eGFR less than 30\u200aml\/min. Lesinurad monotherapy (400\u200amg\/day) associates with serum creatinine elevations. However, this risk is substantially attenuated with coprescription of a XOI and when prescribed at a dose of 200\u200amg\/day. Given its\u2019 modest urate-lowering effect, and the risk of serum creatinine elevation when used alone, it is licenced for use in combination with XOI for people unable to achieve target serum uric acid with XOI alone. Lesinurad does not have the drug interactions associated with probenecid, however, it is metabolized by CYP2C9, and should be used with caution if CYP2C9 inhibitors are coprescribed. Arhalofenate also acts by blocking URAT-1; however, it also blocks the NALP-3 inflammasome providing gout-specific anti-inflammatory effect. Arhalofenate has a weaker urate-lowering effect than lesinurad and further phase III evaluation is planned.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Summary<\/jats:title>\n            <jats:p>Lesinurad provides an additional option for people with gout unable to achieve target serum uric acid with XOI alone.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/bor.0000000000000476","type":"journal-article","created":{"date-parts":[[2017,12,14]],"date-time":"2017-12-14T15:15:06Z","timestamp":1513264506000},"page":"177-182","source":"Crossref","is-referenced-by-count":10,"title":["New urate-lowing therapies"],"prefix":"10.1097","volume":"30","author":[{"given":"Abhishek","family":"Abhishek","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20230928","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1136\/annrheumdis-2013-204463","article-title":"Rising burden of gout in the UK but continuing suboptimal management: a nationwide population study","volume":"74","author":"Kuo","year":"2015","journal-title":"Ann Rheum Dis"},{"key":"R2-20230928","doi-asserted-by":"crossref","first-page":"3136","DOI":"10.1002\/art.30520","article-title":"Prevalence of gout and hyperuricemia in the US general population: the National Health and Nutrition Examination Survey 2007\u20132008","volume":"63","author":"Zhu","year":"2011","journal-title":"Arthritis Rheum"},{"key":"R3-20230928","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1002\/acr.21772","article-title":"2012 American College of Rheumatology Guidelines for Management of Gout Part I: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res"},{"key":"R4-20230928","doi-asserted-by":"crossref","first-page":"1447","DOI":"10.1002\/acr.21773","article-title":"2012 American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis","volume":"64","author":"Khanna","year":"2012","journal-title":"Arthritis Care Res"},{"key":"R5-20230928","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/rheumatology\/kex156","article-title":"The British Society for Rheumatology guideline for the management of gout","volume":"56","author":"Hui","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"R6-20230928","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/annrheumdis-2016-209707","article-title":"2016 updated EULAR evidence-based recommendations for the management of gout","volume":"76","author":"Richette","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R7-20230928","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1136\/annrheumdis-2016-209213","article-title":"Lesinurad in combination with allopurinol: a randomised, double-blind, placebo-controlled study in patients with gout with inadequate response to standard of care (the multinational CLEAR 2 study)","volume":"76","author":"Bardin","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"R8-20230928","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1002\/art.40159","article-title":"Lesinurad, a selective uric acid reabsorption inhibitor, in combination with febuxostat in patients with tophaceous gout: findings of a phase III clinical trial","volume":"69","author":"Dalbeth","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"R9-20230928","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/s13075-016-1107-x","article-title":"Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney","volume":"18","author":"Miner","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"R10-20230928","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1136\/annrheumdis-2015-207919","article-title":"Lesinurad in combination with allopurinol: results of a phase 2, randomised, double-blind study in patients with gout with an inadequate response to allopurinol","volume":"75","author":"Perez-Ruiz","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R11-20230928","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1002\/art.39840","article-title":"Lesinurad combined with allopurinol: a randomized, double-blind, placebo-controlled study in gout patients with an inadequate response to standard-of-care allopurinol (a US-based study)","volume":"69","author":"Saag","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"R12-20230928","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1093\/rheumatology\/kex350","article-title":"Lesinurad monotherapy in gout patients intolerant to a xanthine oxidase inhibitor: a 6 month phase 3 clinical trial and extension study","volume":"56","author":"Tausche","year":"2017","journal-title":"Rheumatology (Oxford)"},{"key":"R13-20230928","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1002\/art.39684","article-title":"A randomized, double-blind, active- and placebo-controlled efficacy and safety study of arhalofenate for reducing flare in patients with gout","volume":"68","author":"Poiley","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"R14-20230928","doi-asserted-by":"crossref","first-page":"374","DOI":"10.3899\/jrheum.161062","article-title":"The pharmacodynamics, pharmacokinetics, and safety of arhalofenate in combination with febuxostat when treating hyperuricemia associated with gout","volume":"44","author":"Steinberg","year":"2017","journal-title":"J Rheumatol"},{"key":"R15-20230928","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nature742","article-title":"Molecular identification of a renal urate anion exchanger that regulates blood urate levels","volume":"417","author":"Enomoto","year":"2002","journal-title":"Nature"},{"key":"R16-20230928","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/j.1440-1797.2010.01368.x","article-title":"Interactions of urate transporter URAT1 in human kidney with uricosuric drugs","volume":"16","author":"Shin","year":"2011","journal-title":"Nephrology (Carlton)"},{"key":"R17-20230928","doi-asserted-by":"crossref","first-page":"155","DOI":"10.4103\/0976-500X.195897","article-title":"Lesinurad: a significant advancement or just another addition to existing therapies of gout?","volume":"7","author":"Gupta","year":"2016","journal-title":"J Pharmacol Pharmacother"},{"key":"R18-20230928","doi-asserted-by":"crossref","first-page":"3555","DOI":"10.2147\/DDDT.S119944","article-title":"Effects of renal function on pharmacokinetics and pharmacodynamics of lesinurad in adult volunteers","volume":"10","author":"Gillen","year":"2016","journal-title":"Drug Des Devel Ther"},{"key":"R19-20230928","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1093\/ckj\/sfx036","article-title":"Lesinurad: what the nephrologist should know","volume":"10","author":"Sanchez-Ni\u00f1o","year":"2017","journal-title":"Clin Kidney J"},{"issue":"(Suppl)","key":"R20-20230928","first-page":"S697","article-title":"Arhalofenate is a novel dual-acting agent with uricosuric and anti-inflammatory properties","volume":"64","author":"Choi","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"(Suppl 3)","key":"R21-20230928","first-page":"450","article-title":"Arhalofenate a novel uricosuric agent, is an inhibitor of human uric acid transporters","volume":"71","author":"Lavan","year":"2013","journal-title":"Ann Rheum Dis"},{"key":"R22-20230928","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nature04516","article-title":"Gout-associated uric acid crystals activate the NALP3 inflammasome","volume":"440","author":"Martinon","year":"2006","journal-title":"Nature"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00002281-201803000-00008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,28]],"date-time":"2023-09-28T02:03:47Z","timestamp":1695866627000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002281-201803000-00008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,3]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/bor.0000000000000476","relation":{},"ISSN":["1040-8711","1531-6963"],"issn-type":[{"value":"1040-8711","type":"print"},{"value":"1531-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,3]]}}}